Caseware UK (AP4) 2023.0.135 2023.0.135 2023-11-302023-11-301No description of principal activityThe members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.true12022-12-01falsefalsefalse 10480336 2022-12-01 2023-11-30 10480336 2021-12-01 2022-11-30 10480336 2023-11-30 10480336 2022-11-30 10480336 c:Director1 2022-12-01 2023-11-30 10480336 d:CurrentFinancialInstruments 2023-11-30 10480336 d:CurrentFinancialInstruments 2022-11-30 10480336 d:CurrentFinancialInstruments d:WithinOneYear 2023-11-30 10480336 d:CurrentFinancialInstruments d:WithinOneYear 2022-11-30 10480336 d:ShareCapital 2023-11-30 10480336 d:ShareCapital 2022-11-30 10480336 d:RetainedEarningsAccumulatedLosses 2023-11-30 10480336 d:RetainedEarningsAccumulatedLosses 2022-11-30 10480336 c:FRS102 2022-12-01 2023-11-30 10480336 c:AuditExempt-NoAccountantsReport 2022-12-01 2023-11-30 10480336 c:FullAccounts 2022-12-01 2023-11-30 10480336 c:PrivateLimitedCompanyLtd 2022-12-01 2023-11-30 10480336 2 2022-12-01 2023-11-30 10480336 e:PoundSterling 2022-12-01 2023-11-30 iso4217:GBP xbrli:pure

Registered number: 10480336









GENETICS LONDON LTD







UNAUDITED

FINANCIAL STATEMENTS

FOR THE YEAR ENDED 30 NOVEMBER 2023

 
GENETICS LONDON LTD
REGISTERED NUMBER: 10480336

BALANCE SHEET
AS AT 30 NOVEMBER 2023

2023
2022
Note
£
£

  

Current assets
  

Debtors: amounts falling due within one year
 4 
137,584
126,478

Cash at bank and in hand
 5 
28,462
36,615

  
166,046
163,093

Creditors: amounts falling due within one year
 6 
(72,197)
(42,142)

Net current assets
  
 
 
93,849
 
 
120,951

Net assets
  
93,849
120,951


Capital and reserves
  

Called up share capital 
  
1
1

Profit and loss account
  
93,848
120,950

  
93,849
120,951


The director considers that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the statement of income and retained earnings in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf on 29 November 2024.




Melita Irving
Director

The notes on pages 2 to 4 form part of these financial statements.
Page 1

 
GENETICS LONDON LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 NOVEMBER 2023

1.


General information

Genetics London Ltd ("the Company") is a Company limited by shares, incorporated in England and Wales. Its registered office is Leytonstone House, 3 Hanbury Drive, Leytonstone, London, E11 1GA.
The principal activity of the Company during the period was that of provision of specialist medical practices.

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland' and the requirements of the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The following principal accounting policies have been applied:

 
2.2

Revenue

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured. Revenue is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. The following criteria must also be met before revenue is recognised:

Rendering of services

Revenue from a contract to provide services is recognised in the period in which the services are provided in accordance with the stage of completion of the contract when all of the following conditions are satisfied:
the amount of revenue can be measured reliably;
it is probable that the Company will receive the consideration due under the contract;
the stage of completion of the contract at the end of the reporting period can be measured reliably; and
the costs incurred and the costs to complete the contract can be measured reliably.

 
2.3

Interest income

Interest income is recognised in profit or loss using the effective interest method.

 
2.4

Finance costs

Finance costs are charged to profit or loss over the term of the debt using the effective interest method so that the amount charged is at a constant rate on the carrying amount. Issue costs are initially recognised as a reduction in the proceeds of the associated capital instrument.

Page 2

 
GENETICS LONDON LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 NOVEMBER 2023

2.Accounting policies (continued)

 
2.5

Taxation

Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the balance sheet date in the countries where the Company operates and generates income.

 
2.6

Debtors

Short-term debtors are measured at transaction price, less any impairment. 

 
2.7

Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. 

 
2.8

Creditors

Short-term creditors are measured at the transaction price.

 
2.9

Dividends

Equity dividends are recognised when they become legally payable. Interim equity dividends are recognised when paid. Final equity dividends are recognised when approved by the shareholders at an annual general meeting.


3.


Employees




The average monthly number of employees, including the director, during the year was 1 (2022 - 1).


4.


Debtors

2023
2022
£
£


Trade debtors
4,644
11,704

Other debtors
132,940
114,774

137,584
126,478


Page 3

 
GENETICS LONDON LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 NOVEMBER 2023

5.


Cash and cash equivalents

2023
2022
£
£

Cash at bank and in hand
28,462
36,615



6.


Creditors: Amounts falling due within one year

2023
2022
£
£

Trade creditors
4,020
3,420

Corporation tax
64,177
35,722

Accruals and deferred income
4,000
3,000

72,197
42,142



7.


Transactions with directors

During the period, the Company advanced £134,742 (2022 - £114,503) to the director and the director repaid £118,836 (2022 - £43,274). At the period end, the director owed the Company £132,940 (2022 - £114,774). Interest of £2,260 (2022 - £1,987) is charged on the overdrawn loan accounts at the HM Revenue & Customs official rate.
 
Page 4